Health Care Related Organization

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

2 days ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

4 days ago talkbio0Tagged biotech collaboration, Camurus, cardiometabolic health, Drug Development, eli lilly, FluidCrystal technology, incretin drugs, long-acting therapies, Obesity, pharma partnerships

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

4 days ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025

5 days ago talkbio0Tagged Adjuvant Melanoma, ASCO, Clinical Trials, lymphocyte-activation gene 3 protein, human, Malignant neoplasm of lung, Myers, Opdivo, Opdualag, relatlimab, squibb

Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

5 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

5 days ago talkbio0Tagged Asthma, biotech collaboration, DEL-AI, Dermatitis, Atopic, Drug Discovery, Licensing Deal, Nurix, NX-3911, protein degrader, sanofi, STAT6

Sanofi; Nurix Therapeutics; STAT6; NX-3911; protein degrader; atopic dermatitis; asthma; drug discovery; licensing deal; DEL-AI platform; biotech collaboration

Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound

5 days ago talkbio0Tagged Biopharma, eli lilly, GLP-1/GIP receptor agonist, Hansoh Pharmaceuticals, HS-20094, Licensing Deal, Obesity, Regeneron, Zepbound

Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus

5 days ago talkbio0Tagged Acquisition, Ayvakit, Biopharma, Blueprint Medicines, elenestinib, Immunology, Infrequent, Mastocytosis, Systemic, pipeline, sanofi

Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations

6 days ago talkbio0Tagged age restriction, Approved, conditions, COVID19 (disease), Effectiveness, mNEXSPIKE, Moderna, mRNA-1283, next-generation vaccine, respiratory virus season, United States Food and Drug Administration, Vaccines

Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy